Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

Buzz on the Bullboards: Sell in May and go away?

As investors assess the strategy of liquidating positions before the summer, lingering concerns over an impending economic recession haven’t appeared to slow down activity on the Bullboards. Instead, as we approach zero hour on the deadline to settle t...
Jonathon Brown | May 25, 2023 |

Why Fortune Favours Chris Taylor’s Kodiak Copper

It’s a stark new reality. And investors need to listen up or lose out. Truth be told, it is no longer only the size and grade of each new mineral discovery that determines whether it can become a mine. Now, all exploration/development projects also need to ...
Marc Davis | January 24, 2022 |

Canagold: Sweet Surprise as a High-Grade Low-Cost Gold Deposit Delivers

It’s a big shot in the arm that promises to redouble the considerable scarcity value of the New Polaris gold deposit. A one-million-ounce gold deposit that is owned by Canagold Resources ( TSX: CCM ) (OTCBB: CRCUF) ( Frankfurt: CANA), New Polaris may be ...
Marc Davis | September 22, 2021 |

Unique Value-Added Antiviral Vaccine Technology Platform

(Click to play video.) Founded in 2018 to improve on protein haptenization and leverage previous vaccine development in the field, Vancouver, BC-based BioVaxys Technology Corp . ( CSE.BIOV , OTCQB: BVAX , Forum ) is a clinical stage biotechnology company that...
Dave Jackson | September 14, 2021 |

XPhyto: Buyouts, Biosensors and a Booming Business

Test, test, test! It’s the World Health Organization’s battle cry in the global war against COVID-19 and other coronaviruses – including future outbreaks. And it is not getting any less resonant as new variants continue to cause ha...
Marc Davis | August 3, 2021 |

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...
Marc Davis | June 25, 2021 |

XPhyto: Proof of Concept for Mescalin Synthesis

It’s become a much talked-about story on both sides of the Atlantic. XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTCQB: XPHYF) has earned considerable media coverage in recent months due to its expansion into the development of psychedelic d...
Marc Davis | June 9, 2021 |

XPhyto Therapeutics: Are they Selling the Solution to Germany’s Rapid Testing Crisis?

The Germans call it COVID-19 “rapid testing mania”. But like most manias, it has opened up a Pandora’s box of problems. As the speed of the vaccine rollout program falters in Europe, on-the-spot antigen testing continues to be the ...
Marc Davis | June 2, 2021 |

A Life Sciences Project Accelerator Kicks into High Gear

XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTC: XPHYF) has been a hot story lately, especially in Germany, due to its recent commercialization of a super-fast PCR test kit for definitively diagnosing COVID-19 infections in point-of-care settings. The company rec...
Marc Davis | May 10, 2021 |
1 2 3 4 5 6 7 8 9